key: cord-0847663-g4udms7y authors: Giampiero, Capobianco; Laura, Saderi; Stefano, Aliberti; Michele, Mondoni; Andrea, Piana; Francesco, Dessole; Margherita, Dessole; Luigi, Cherchi Pier; Salvatore, Dessole; Giovanni, Sotgiu title: COVID-19 in pregnant women: A systematic review and meta-analysis date: 2020-07-16 journal: Eur J Obstet Gynecol Reprod Biol DOI: 10.1016/j.ejogrb.2020.07.006 sha: 725d588fa10020856f2f37f0a6a5bb07d1406d88 doc_id: 847663 cord_uid: g4udms7y OBJECTIVE: Coronavirus disease 2019 (COVID-19) is a novel infectious disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Several reports highlighted the risk of infection and disease in pregnant women and neonates. To assess the risk of clinical complications in pregnant women and neonates infected with SARS-CoV-2 carrying out a systematic review and meta-analysis of observational studies. DATA SOURCES: Search of the scientific evidence was performed using the engines PubMed and Scopus, including articles published from December 2019 to 15 April 2020. STUDY ELIGIBILITY CRITERIA: Only observational studies focused on the assessment of clinical outcomes associated with pregnancy in COVID-19 women were selected. STUDY APPRAISAL AND SYNTHESIS METHODS: The first screening was based on the assessment of titles and abstracts, followed by the evaluation of full-texts. Qualitative variables were summarized with frequencies, whereas quantitative variables with central and variability indicators depending on their parametric distribution. Forest plots were used to describe point estimates and in-between studies variability. Study quality assessment was performed. RESULTS: Thirteen studies were selected. All of them were carried out in China. The mean (SD) age and gestational age of pregnant women were 30.3 (1.5) years and 35.9 (2.9) weeks, respectively. The mean (SD) duration from the first symptoms to the hospital admission and to labour were 5.5 (2.0) and 9.5 (8.7) days, respectively. Patients mainly complained of fever and cough (pooled (95% CI) proportions were 76.0% (57.0%-90.0%) and 38.0 (28.0%-47.0%), respectively). Several antibiotics, antivirals, and corticosteroids were prescribed in different combinations. The pooled prevalence of maternal complications and of caesarean section were 45.0% (95% CI: 24.0%-67.0%) and 88.0% (95%CI: 82.0%-94.0%). A proportion of pregnant women less than 20% were admitted to ICU. The pooled proportion of preterm infants was 23.0% (95%CI: 11.0%-39.0%). The most frequent neonatal complications were pneumonia and respiratory distress syndrome. The pooled percentage of infected neonates was 6.0% (95%CI: 2.0%-12.0%). CONCLUSIONS: The present study suggests a high rate of maternal and neonatal complications in infected individuals. However, the current scientific evidence highlights a low risk of neonatal infection. Multicentre, cohort studies are needed to better elucidate the role of SARS-CoV-2 during pregnancy. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a novel virus which can cause severe pulmonary and extra-pulmonary disease and death. SARS-CoV-2-related disease (COVID-19) can affect more frequently elderly persons and individuals with cardiologic, respiratory, renal, and metabolic comorbidities 1 . Pregnancy can compromise the immune system and potentially SARS-CoV-2 infection can increase the risk of pneumonia in pregnant women in comparison to non-pregnant women 2 . No clear scientific evidence has been provided on the vertical transmission of SARS-CoV-2 (infection in utero from an infected mother to her infant before birth) [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] . The aim of the present systematic review and meta-analysis is to assess the clinical features and outcomes of pregnant women and neonates following SARS-CoV-2 infection, as well as the risk of vertical transmission, if any. Two electronic search engines (i.e., PubMed and Scopus) were chosen to detect the manuscripts on the topic "COVID-19 and pregnancy". The selection of the scientific evidence was based on the identification of mother-, fetus-, and newbornoutcomes. The search included articles published from December 2019 to 15 April 2020. The search was restricted to manuscripts written in English language and published in peer-reviewed journals. Several keywords, combined in different strings depending on the electronic database, were chosen: "pregnancy", "mother", "child", "mother-to-child transmission", "COVID-19", and "SARS-CoV-2". To improve the diagnostic accuracy of the search a manual assessment of the list of references was performed. Reports published in the grey literature or in the social and conventional media were excluded following the risk of unreliable and poor scientific information on the adopted methodology. The following exclusion criteria were adopted: 1) editorials, reviews, correspondences; 2) studies performed in vitro; 3) studies which recruited animals. Titles and abstracts (if any) were screened to evaluate the suitability of the manuscript based on the abovementioned inclusion and exclusion criteria. The first assessment, carried out by two investigators (LS and AP), was supervised by a third investigator (GS). The assessment of the selected full texts, as well as the extraction of the outcome and independent variables, was performed by the same investigators. An ad hoc electronic form (excel file) was prepared to collect qualitative and quantitative variables. Two investigators (LS and AP) independently retrieved data from the results sections of the selected articles. Discrepancies (<5%) were discussed and addressed by a third investigator (GS). The inter-rater agreement was ~100%. Anonymized information was retrieved from the full-texts articles. In the majority of the cases data were aggregated. On this basis, a local ethical approval was not needed. The following study-, pregnant, and neonate-related variables were collected: 1) first author; 2) publication year; 3) study period; 4) country/ies where the study was performed; 5) epidemiological study design; 6) clinical setting/s; 7) gender of the neonate; 8) age of the mother and of the neonate; 9) mode of delivery; 10) Complications of the mother and of the neonate/s; 11) therapy prescribed to the pregnant and to the neonate/s; 12) Apgar score; 13) SARS-CoV-2 infection of the neonate/s; 14) clinical, laboratory, radiological variables associated with the infection of the mother and of the neonate; 15) clinical outcomes of the mother and of the newborn. The steps of the review process, from study selection to data collection, were performed by investigators whose agreement was ~100%. Both the systematic review and meta-analysis were conducted following the recommendations of the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) (Moher D, et al. The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med. 2009). The Scottish Intercollegiate Guidelines Network was adopted to assess the quality of the studies with the observational design 13 . Case-report and case-series were evaluated following the ad hoc quality scale "Methodological quality and synthesis of case-series and case-reports" 14 . Qualitative variables were summarized with absolute and relative (percentage) frequencies, whereas quantitative variables were described with means (standard deviations, SD, or ranges). Forest plots were used to describe point (95% confidence intervals, CI) estimates and in-between studies' variability. The inconsistency indicator (I 2 ) was chosen to show the relationship between true variability and overall variation, with low, medium, and high heterogeneity in case of the following values: <25%, ≥25%-<50%, and ≥50%, respectively. Fixed and random-effects models were computed keeping into consideration the expected between-study heterogeneity. Inconsistency among the studies was evaluated with the chi-squared test for heterogeneity. Bias assessment plots and Egger weighted regression test methods were used to assess the publication bias. Statistically significance was considered when a two-tailed p-value was <0.05. All the analyses were carried out with the statistical softwares StatsDirect version 3.1.12 (StatsDirect Ltd.) and STATA version 15 (StatsCorp, College Station, Texas, USA). The records found in the search databases were 32 ( Figure 1 ), with 32 full texts carefully evaluated for their inclusion. Only 13 (40.6%) were considered suitable for the qualitative and quantitative analyses. They other papers were excluded for the following reasons: articles written in Chinese language (n= 3), missing information on pregnancy and transmission of SARS-CoV-2 (n= 2), reviews, letters, editorials, commentaries, recommendations (n= 14). All the studies were performed in the years 2019 15 and 2020 2-4,6,7,8-10,15-18 (from December 2019 15 to March 2020 18 ) and the manuscripts were published in the year 2020 2-10,15-18 ( Table 1 ). The types of the studies were casereports (5, 38.5%) 2, 4, 5, 9, 18 , case-series (2, 15.4%) 3, 8 , and observational studies (6, 46.2%) 6, 7, 10, [15] [16] [17] . The design of the observational studies was described as retrospective and as cohort study in five (85.7%) 6,7,10,15,16 and in two (28.6%) 7,17 manuscripts, respectively. The studies were conducted in China 2-10,15-18 , mainly in Hubei province [3] [4] [5] [6] [7] [8] 10, [15] [16] [17] [18] . Monocentre studies were eleven (84.6%) 2-5,7-10,16-18 , whereas only two (15.4%) 6, 15 were multicentre studies. The number of enrolled individuals ranged from 1 (23.1%) 2, 9, 18 to 33 (7.7%) 17 (Table 2 ). The total number of individuals recruited in the present analysis was 114, who were COVID-19 positive. The mean (SD) age was 30.3 (1.5) years, ranging from 22 15 to 40 3,10 years. The mean (SD) gestational age was 35.9 (2.9) weeks. The information on contact with a contagious patient was reported in 8 (61.5%) [2] [3] [4] 8, 9, 15, 16, 18 studies, whereas data on infectious patients in the family was described by 5 (38.5%) 2-4,15,18 studies. The mean (SD) duration from the start of the symptoms and clinical signs to the hospital admission was 5.5 (2.0) days, but it was reported only by 5 (38.5%) 2,4,8,10,18 studies. The mean duration from the occurrence of the first symptoms and clinical signs to the delivery was 9.5 (8.7) days, even if the information was provided only by six studies [2] [3] [4] 6, 8, 18 . The most prevalent symptoms and clinical signs were cough 2,3,5,6-8,10,16,17 (9, 69.2%), fever 2-6,8,10,15-18 (11, 84.6%), myalgia 3,5,10 (3, 23.1%), fatigue 3,10,15 (3, 23.1%), sore throat 3,4,6,10 (4, 30.8%), dyspnoea 3,5,10,15 (4, 30.8%), and lymphopenia 3,5,10 (3, 23.1%). Body temperature in pregnant women ranged from 36.5°C 3 to 39.0°C 10, 15 . The pooled proportion of fever and cough was 76.0% (95% CI: 57.0%-90.0%; I 2 : 70.9%) and 38.0% (95% CI: 28.0%-47.0%; I 2 : 25.3%), respectively (Figures 2 and 3 ). Interventions prescribed to pregnant women during the hospital stay were: corticosteroids (5, 38.5%) 2, 4, 9, 16, 18 , antibiotics (8, 61.5%) [2] [3] [4] [8] [9] [10] 16, 18 , antivirals (9, 69.2%) [2] [3] [4] 6, [8] [9] [10] 16, 18 , and oxygen therapy (5, 38.5%) 3, 8, 10, 16, 18 (Table 3) . In particular, oseltamivir was prescribed in two (15.4%) 4,16 studies, lopinavir/ritonavir in two (15.4%) 2,9 studies, inhaled atomized peg-interferon and ganciclovir in two (15.4%) 8, 16 studies, and arbidol in three (23.1%) 8, 9, 16 studies. Methylprednisolone was administered in two (15.4%) 2,4 studies, whereas dexamethasone in one (7.7%) 9 study. The following antibiotics were given: cefoperazone sulbactam sodium in one (15.4%) 2,9 studies, azithromycin and ceftazidime in one (7.7%) 4 study, cephalosporins combined with fluoroquinolones and macrolides in one (7.7%) 16 study. Clinical and laboratory characteristics in pregnant women were variable: pneumonia was clinically diagnosed in all recruited women in all selected studies [2] [3] [4] [5] [6] [8] [9] [10] [16] [17] [18] , with the only exception of one 7 study where only 6.3% showed a pneumonia and one 15 study where the information on pneumonia was not provided (Table 4 ). CTbased diagnosis of pneumonia was performed in 88.9% 3 -100% 2,4-6,8-10,16-18 women per single study. The most frequent complications during pregnancy were: non-reassuring fetal testing (5, 38.5%) 2,3,6,7,15 , premature rupture of membranes (5, 38.5%) 3,6,7,15,17 , placenta praevia (3, 23.1%) 5,6,10 , preeclampsia (2, 15.4%) 3,7 , uterine rupture (2, 15.4%) 7,16 , gestational diabetes (2, 15.4%) 7,10 , hypertension (1, 7.7%) 3 , cholecystitis (1, 7.7%) 5 , abnormal amniotic fluid (1, 7.7%) 6 , umbilical cord abnormalities (1, 7.7%) 6 , foetal asphyxia (1, 7.7%) 7 , meconium staining (1, 7.7%) 7 , and stillbirth (1, 7.7%) 15 . The pooled prevalence of complications in pregnant women was 45.0% (95% CI: 24.0%-67.0%; I 2 : 76.3%) ( Figure 4 ). Caesarean section was described in all studies 2-10,13-16 and was carried out from 66.7% 8 to 100% [2] [3] [4] 7, 13, 14, 16 (53.9% of all studies) women. The pooled proportion of caesarean section was 88.0% (95% CI: 82.0%-94.0%; I 2 : 9.2%) ( Figure 5 ). The information on admission to intensive care units was provided by eight (61.5%) 2, 4, 5, 8, 9, 13, 16, 18 studies: from 0% 2,4,8,16,18 to 100% 9 women were admitted for severe disease per single study. The pooled percentage of women admitted to ICU was 13.0% (95% CI: 4.0%-25.0%; I 2 : 0.0%) ( Figure 6 ). Cure rate (i.e., clinical and/or virologic recovery) was described in five (38.5%) studies. No women (0.0%) died 2-10,15-18 . Preterm neonates were described in all 2-9,15-18 studies than one 10 : their proportion ranged from 0.0% 2, 4, 5, 8, 16, 18 to 100.0% 9 ( Table 5 ). The pooled proportion of preterm infants was 23.0% (95% CI: 11.0%-39.0%; I 2 : 59.6%) ( Figure 7 ). The mean (SD) weight at birth was 2,924.7 (490.8) g in 9 (69.2%) 3-9,16,18 studies. Apgar score at one and ten minutes after birth ranged from 7 5,6 to 10 6 and from 8 5,6 to 10 3,4,6,9,16,18 , respectively. Complications of the neonates were: fever was described in 3 (23.1%) 4,6,17 studies, pneumonia in 3 (23.1%) 4,7,17 studies, respiratory distress syndrome in 2 (7.7%) 6,17 studies, infection in 2 (7.7%) 6,16 studies, low birth weight in 1 (7.7%) 3 study, lymphopenia in 1 (7.7%) 4 study, abdominal distension in 1 (7.7%) 4 study, skin rash in 1 (7.7%) 5 study, oedema in 1 (7.7%) 5 study, transient tachypnoea in 1 (7.7%) 5 study, shortness of breath in 1 (7.7%) 17 study, rapid heart rate in 1 (7.7%) 6 study, gastro-intestinal symptoms in 1 (7.7%) 6 study, feeding intolerance in 1 (7.7%) 15 study, pneumothorax in 1 (7.7%) 6 study, meconium stained amniotic fluid in 1 (7.7%) 8 study, slight decreased responsiveness and muscle tension in 1 (7.7%) 8 study, cyanosis in 1 (7.7%) 15 study, and abnormal cytokine test results in 1 (7.7%) 4 study. The pooled proportion of neonates born with complications was 39.0% (95% CI: 18.0%-63.0%; I 2 : 71.8%) (Figure 8 ). SARS-CoV-2 infection was found in four neonates and was described in two (15.4%) studies 16, 17 , whereas 2 died in two (15.4%) studies 6, 15 . One patient developed refractory shock, multiple organ failure, and disseminated intravascular coagulation eight days after birth; no information was provided for the other one. The pooled percentage of infected neonates was 6.0% (95% CI: 2.0%-12.0%; I 2 : 0.0%) (Figure 9 ). Publication bias and quality assessment are described in the Figures 10-17 and Tables 6-7. The methodological quality was poor. The present systematic review and meta-analysis showed a high risk of severe maternal and neonatal complications in case of SARS-CoV-2 infection. COVID-19 is an infectious disease whose incidence is highest in elderly individuals and in patients with cardiovascular, respiratory, renal, and metabolic comorbidities 19-23 . Immunocompromised individuals could be at risk of pulmonary and/or extra-pulmonary conditions during respiratory infections 24,25 . Pregnant women can show a qualitative and quantitative impairment of their immune system, which can increase the probability of respiratory infections and, then, severe infectious diseases 26,27 . The first cases of severe COVID-19 were described at the end of December 2019 and its incidence has been seemed heterogeneous 28 . Cases of SARS-CoV-2 infection and disease of pregnant women have been described in reports and series [2] [3] [4] [5] 8, 9, 18 . Concerns have been raised on the risk of severe disease, vertical transmission, and foetal and neonatal complications. The present systematic review and meta-analysis is aimed at describing the current scientific evidence on COVID-19 in pregnant females and on the neonatal risk of infection and disease. To the best of our knowledge, this is the first study focused on the assessment of the clinical characteristics of COVID-19 in pregnancy. All the scientific studies were performed in China 2-10,15-18 , mainly in the most affected province of Hubei 3-8,10,15-18 . The number of the described cases was not high both for pregnant women and neonates. However, a first focus on the clinical impact of COVID-19 during pregnancy can help clinicians and policymakers to better manage future cases of disease. Fever and cough seem the most prevalent symptoms and clinical signs of the disease in the population group of pregnant women. Other respiratory symptoms were reported, with few or absent extrapulmonary manifestations. Cases were probably selected and do not adequately describe the real impact of the disease in the population group: pneumonia was diagnosed in about all selected studies. Although women were heterogeneously treated (from antibiotics, to antivirals, to corticosteroids, in different combinations), 45.0% of infected women shows pregnancy-related complications, with non-reassuring fetal testing, premature rupture of membranes, and placenta praevia being the most frequently reported. Caesarean section was performed in more than 50% of the cases, but a clear explanation of the rationale or reasons behind that surgical intervention were not provided. A relatively high pooled proportion of pregnant women (13.0%) were admitted to the ICU. No cases of deaths were notified. The absence of deaths can be explained by the young age of the infected patients; it has been proved that the mortality rate in COVID-19 patients is high in elderly individuals and in those patients with at least one comorbidity. We hypothesize that pregnancy-related immunological changes do not significantly affect the response against SARS-CoV-2. The proportion of infected neonates was low (6%), highlighting a low probability of vertical transmission. However, two neonates died. Furthermore, a pooled neonatal complication rate of 39.0% (95% CI: 18.0%-63.0%) was found. The types of clinical conditions diagnosed in newborns were variable: fever, pneumonia, and respiratory distress syndrome were the most incident, underscoring a respiratory tropism of the virus in neonates and their mothers. The percentage of preterms varied from 0% to 100% in the selected studies (pooled percentage was 23.0%), whereas the weight at birth was less than 3 Kg in the majority of the selected studies. The health of the neonate was good during the labour and outside the mother's womb, with the 1-and 10-minute Apgar score ranging from seven to ten. Timing of the infection was not clarified by the studies. This point needs to be evaluated in future incidence studies in order to understand if there is a more frequent vulnerability period. It is unclear whether the infection is acquired in uterine, during vaginal delivery of after birth. A recent article on ten not pregnant women with severe COVID-19 pneumonia stated that SARS-CoV-2 virus is not found in vaginal fluids. Thus, in theory, vaginal delivery could be allowed 29 . However, the pooled proportion of caesarean section was 88.0%. A systematic review and meta-analysis of Di Mascio et al. 30 reported that COVID-19 is associated with a high rate of miscarriage, preterm birth, pre-eclampsia, caesarean, and perinatal death. A systematic review on 51 women described a high rate of preterm caesarean delivery 31 . Furthermore, a study on 116 Chinese pregnant women showed that no increased risk of spontaneous abortion and preterm birth was found 32 . Several study limitations can be raised: the findings are based on studies whose methodological quality is poor (e.g., case-reports and case-series). All the studies were carried out in China and the inference can be affected by genetic and environmental factors which could have influenced the natural history of the disease. The sample size of the pooled cohort and of the single study is associated with a poor statistical power: potentially significant differences could not have been assessed. The retrieved scientific reports do not keep into consideration important clinical variables (e.g., maternal comorbidities) which could play a relevant role in the prognosis of the disease. Samples seem recruited by convenience. The women described show clinically diagnosed pneumonia in all articles, with the only exception of two studies. Then, this Authors'-driven selection could partially describe the role of SARS-CoV-2 during pregnancy. The majority of the studies are cross-sectional and retrospective; consequently, they do not appropriately describe the follow-up of infected women and neonates. However, the present scientific evidence can provide useful clinical elements which should be carefully monitored during the assessment of pregnant women. The first experiences carried out in Asia could help better tailor clinical (e.g., diagnostic protocols, prophylactic and therapeutic regimens) and public health (e.g., home and hospital confinement) interventions. Observational prospective, cohort, multicentre studies should be promptly implemented to collect standardized epidemiological and clinical data to better address the challenge of COVID-19 in pregnant women 19 . In conclusion, COVID-19 can cause significant maternal and neonatal morbidity. Public health interventions should be carefully implemented and tailored on those important susceptible groups to reduce the incidence of infection and, then, the risk of major complications. A regular and intensive follow-up is required to detect early the occurrence of clinical conditions. The estimated second epidemic wave should be faced keeping into account the available scientific information to reduce the burden of disease in vulnerable population groups, including pregnant women and neonates. Table 6 . Tool for evaluating the methodological quality of case-reports and case-series The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak -an update on the status Lack of Vertical Transmission of Severe Acute Respiratory Syndrome Coronavirus 2, China. Emerg Infect Dis Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records Perinatal Transmission of COVID-19 Associated SARS-CoV-2: Should We Worry? Infants Born to Mothers With a New Coronavirus (COVID-19). Front Pediatr Clinical analysis of 10 neonates born to mothers with 2019-nCoV pneumonia COVID-19) During Pregnancy: A Case Series. Preprints 2020 A case of 2019 Novel Coronavirus in a pregnant woman with preterm delivery Pregnancy and Perinatal Outcomes of Women With Coronavirus Disease (COVID-19) Pneumonia: A Preliminary Analysis Clinical analysis of pregnant women with 2019 novel coronavirus pneumonia Expert consensus for managing pregnant women and neonates born to mothers with suspected or confirmed novel coronavirus (COVID-19) infection Scottish Intercollegiate Guidelines Network. SIGN 50: a guideline developer's handbook Methodological quality and synthesis of case series and case reports Clinical manifestations and outcome of SARS-CoV-2 infection during pregnancy Clinical features and obstetric and neonatal outcomes of pregnant patients with COVID-19 in Wuhan, China: a retrospective, single-centre, descriptive study Neonatal Early-Onset Infection With SARS-CoV-2 in 33 Neonates Born to Mothers With COVID-19 in Wuhan, China. JAMA Pediatr Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease Respiratory infections in immunocompromised patients SARS-CoV-2 is not detectable in the vaginal fluid of women with severe COVID-19 infection Outcome of Coronavirus spectrum infections (SARS, MERS, COVID 1 -19) during pregnancy: a systematic review and meta-analysis COVID19 during pregnancy: a systematic review of reported cases - J o u r n a l P r e -p r o o f Studies included in qualitative synthesis (n= 13) (meta-analysis)